With revenue unlikely to be a stimulant in 2017 the market will...

With revenue unlikely to be a stimulant in 2017 the market will look to the "game changer" announcement next month to carry the stock through.

OBJ is still very much an R&D company but a well funded one.

2017 may yet provide evidence of revenue growth but my expectations are low in terms of the quantum. They really don't have anything being sold in a mass market. They need to prove that all these years of negotiation will result in volume sales.